Empagliflozin and dapagliflozin, some of the most used SGLT2 inhibitors, have been shown to substantially reduce the risk of hospitalization and mortality associated with HF, regardless of the presence of diabetes, according to clinical evidence. The gene discussed is SLC5A2; the disease is hydrops fetalis.